Ibex Medical Analytics vs Paige
This pairing sets pathology's historic first against its most deployed second read, and the deciding facts changed recently. Paige produced the first FDA authorized AI pathology product, Paige Prostate through the De Novo pathway, and has since pursued foundation model work with a Breakthrough Device designation for pan cancer detection, but it was acquired by Tempus in August 2025 and is no longer an independent vendor. Ibex describes itself as the most widely deployed AI platform in pathology, its cleared prostate product works as a second read that flags cancers missed on initial assessment, a structure that avoids automation bias by running after the pathologist rather than before, and it holds the most complete set of published security and quality certifications in this index's pathology lane. If your failure mode is betting on where computational pathology is heading and Tempus ownership fits your stack, start with Paige. If your failure mode is deploying into routine practice today with attestations your security review will accept, start with Ibex. A Breakthrough designation is a development status, not a clearance.
- The oversight structure is the safety argument: the cleared prostate product runs as a second read after the pathologist, flagging small and rare cancers missed on initial assessment, which structurally avoids automation bias.
- Your security review is the gate: an unusually complete published certification set, graded A on this index's security axis, the standard the rest of the pathology lane is held to.
- Routine clinical deployment breadth: prostate, breast, and gastric solutions described as in routine clinical practice worldwide, with FDA 510(k) clearance on the prostate in vitro diagnostic.
- Regulatory history and pathway: the first FDA authorized AI based digital pathology product, cleared through De Novo, which established the pathway others now follow.
- Foundation model direction: pan cancer detection spanning common and rare variants across multiple tissue types, holding FDA Breakthrough Device designation, a development signal though not a clearance.
- Tempus alignment is a feature for you: as part of Tempus since August 2025, the pathology capability sits inside a broader indexed oncology platform, which suits buyers already in that ecosystem.
Side-by-Side
| Axis | I Ibex Medical Analytics |
P Paige |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Deployment claims for both vendors are vendor published, including Ibex's most widely deployed description. Paige was acquired by Tempus in August 2025 for a reported $81.25 million and is indexed under that ownership; buyers should establish contractual continuity terms, a question this index raises across recently acquired pathology platforms. Breakthrough Device designation is not FDA clearance and confers no marketing authorization. Neither vendor publishes pricing.